Therapy News and Research

RSS

Dyax fourth quarter total revenues decrease to $8.5 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2011.

22 Feb 2012

Routine hepatitis C testing of the middle aged could save thousands of lives: CDC report

Increasing number of people are dying of damaged livers due to hepatitis C infection. Federal health officials are considering whether anyone born between 1945 and 1965 should get a one-time blood test to check if they are harboring the dangerous virus. Two-thirds of people with hepatitis C are in this age group, most unaware that a virus that takes a few decades to do its damage has festered since their younger days.

22 Feb 2012

Combination of key guideline-recommended heart failure therapies improve survival odds

A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvement of up to 90 percent in the odds of survival over two years.

22 Feb 2012

New injectable hydrogel can treat tissue damage from heart attack

University of California, San Diego researchers have developed a new injectable hydrogel that could be an effective and safe treatment for tissue damage caused by heart attacks.

22 Feb 2012

OGF-OGFr axis discovery provides new insights into ovarian cancer

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the presence and integrity of the opioid growth factor receptor (OGFr), which mediates the inhibitory action of opioid growth factor (OGF) on cell proliferation, is a key to understanding the progression and treatment of human ovarian cancer.

22 Feb 2012

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).

22 Feb 2012

Mitochondria may be promising new target for cancer treatment

Mitochondria, tiny structures within each cell that regulate metabolism and energy use, may be a promising new target for cancer therapy, according to a new study. Manipulation of two biochemical signals that regulate the numbers of mitochondria in cells could shrink human lung cancers transplanted into mice, a team of Chicago researchers report in the journal FASEB.

22 Feb 2012

Researchers study specially bred mice to understand annual flu epidemics

As part of a national collaboration, Oregon Health & Science University researchers are studying specially bred mice that are more like humans than ever before when it comes to genetic variation. Through these mice, the researchers hope to better understand and treat an infectious disease that plagues us year in and year out: the flu.

22 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

Telomerase reactivation in malignant cells after genomic instability causes cancer progression

Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive and spread, scientists report in the Feb. 17 issue of Cell.

21 Feb 2012

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

A towering $60,000 bill, a year of fierce, flu-like symptoms and a running risk of depression are among the possible costs of two new hepatitis C treatments. But according to Stanford University health policy researchers, they might be worth it.

21 Feb 2012

ReCor Medical's PARADISE ultrasound platform for achieving renal denervation receives CE mark

ReCor Medical, an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has received the CE mark. PARADISE is designed to treat patients with 'resistant' hypertension, a major risk factor for cardiovascular disease.

20 Feb 2012

Elekta to highlight Clarity with Autoscan at Radiosurgery Society meeting

Clarity soft tissue visualization system now provides an Autoscan option for automated ultrasound scanning from outside of the treatment room, employing a motorized probe positioned at the patient's perineum.

From Elekta 20 Feb 2012

James E. Cary Cancer Center to implement RayStation treatment planning system

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from the James E. Cary Cancer Center located in Hannibal, Missouri.

20 Feb 2012

Charité launches new EU research project to personalize breast cancer treatment

Adjusting breast cancer therapy to individual patients to avoid ineffective treatment: Charité Universitätsmedizin Berlin and eleven partner institutions from six countries have set this as their goal. They have launched the EU research project RESPONSIFY.

20 Feb 2012

Autism may be evident in an infant’s brain much earlier than thought: Study

Researchers have found that autism shows tell tale signs in babies as young as 6 months old — half a year or more before parents typically begin to notice symptoms of the condition. The results shed light on the fundamental differences in the brains of autistic children and could help lead to earlier detection and treatment, says co-author Geraldine Dawson, chief science officer at Autism Speaks, which helped fund the study in today's American Journal of Psychiatry.

20 Feb 2012

Study reveals potential strength of different anti-HIV combination drugs

Using a mathematical formula that carefully measures the degree to which HIV infection of immune system cells is stalled by antiretroviral therapy, AIDS experts at Johns Hopkins have calculated precisely how well dozens of such anti-HIV drugs work, alone or in any of 857 likely combinations, in suppressing the virus. Results of the team's latest research reveal how some combinations work better than others at impeding viral replication, and keeping the disease in check.

19 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012